🇮🇹 REC.MI — Recordati Industria Chimica e Farmaceutica S.p.A.

Salud Mantener
← Volver

Precio actual

53,25 EUR

Máx. histórico

60,95

631 días

Split 4:1 del 18/04/2005

Caída desde máximo

-12,63%

Rango 52 semanas

43,76 – 54,45

Variación hoy

+0,38%

Cierre anterior

53,05

Rango de hoy

52,95 – 53,05

Volumen hoy

283.335

Peor caída histórica

-102,73%

15/02/1996 → 09/05/1996

Aún sin recuperar

Volatilidad anualizada ⓘ

242.233.592.934,14%

Información
Nombre completo
Recordati Industria Chimica e Farmaceutica S.p.A.
Divisa
EUR
Mercado
Milan
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
4.700
PER ⓘ
22,37 (puede no estar actualizado)
Dividend yield
2,67% (puede no estar actualizado)
Precio objetivo analistas
56,73 EUR (puede no estar actualizado)
Primera cotización
24/03/1995
Precio actualizado
hace 2 días
Sobre la empresa

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing's syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing's syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.

Dividendos repartidos Total últimos 12 meses: 1,3400 EUR · Yield: 2,52%
Fecha de pago Importe por participación
18/04/2011 0,2750 EUR
26/04/2010 0,2750 EUR
20/04/2009 0,2500 EUR
21/04/2008 0,2150 EUR
23/04/2007 0,1850 EUR
24/04/2006 0,1375 EUR
25/04/2005 0,1100 EUR
22/04/2005 0,1100 EUR
19/04/2004 0,0938 EUR
22/04/2003 0,0938 EUR
22/04/2002 0,0625 EUR
07/05/2001 75,0000 EUR
08/05/2000 75,0000 EUR
10/05/1999 75,0000 EUR
04/05/1998 75,0000 EUR
Splits Registrados en el histórico de precios
Fecha Ratio
18/04/2005 4:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
29/01/2025 57,75 58,65 57,60 58,15 +1,13% 1,82% 236.877
28/01/2025 57,00 57,80 56,90 57,50 +1,23% 1,58% 422.629
27/01/2025 56,00 56,80 55,90 56,80 +1,43% 1,61% 399.735
24/01/2025 55,90 56,30 55,75 56,00 +0,36% 0,98% 533.536
23/01/2025 55,75 55,85 55,35 55,80 +0,09% 0,90% 281.765
22/01/2025 55,15 55,85 55,10 55,75 +1,09% 1,36% 316.309
21/01/2025 54,55 55,20 54,40 55,15 +1,01% 1,47% 205.331
20/01/2025 54,80 55,05 54,60 54,60 -0,55% 0,82% 223.711
17/01/2025 54,80 55,10 54,15 54,90 +0,64% 1,73% 624.555
16/01/2025 54,30 54,65 54,10 54,55 +0,65% 1,01% 281.722
15/01/2025 52,65 54,20 52,65 54,20 +2,94% 2,94% 334.810
14/01/2025 52,75 53,15 52,45 52,65 +0,10% 1,33% 241.147
13/01/2025 53,30 53,35 52,50 52,60 -1,41% 1,59% 350.832
10/01/2025 53,80 54,00 53,25 53,35 -1,20% 1,39% 231.861
09/01/2025 53,05 54,20 53,05 54,00 +1,22% 2,17% 213.289
08/01/2025 52,55 53,35 52,20 53,35 +1,43% 2,19% 283.523
07/01/2025 51,50 52,60 51,35 52,60 +1,54% 2,43% 212.091
06/01/2025 51,40 51,80 51,15 51,80 +0,88% 1,26% 182.800
03/01/2025 51,75 51,85 51,35 51,35 -0,77% 0,97% 182.789
02/01/2025 50,65 51,75 50,65 51,75 +2,27% 2,17% 167.566
30/12/2024 50,95 51,00 50,55 50,60 -0,59% 0,88% 186.789
27/12/2024 50,30 51,05 49,60 50,90 +0,79% 2,88% 161.858
23/12/2024 50,20 50,95 49,96 50,50 +0,20% 1,97% 209.209
20/12/2024 50,05 50,45 49,16 50,40 +0,10% 2,58% 505.963
19/12/2024 50,30 50,45 49,86 50,35 -0,79% 1,17% 373.904
18/12/2024 50,65 50,85 50,35 50,75 +0,30% 0,99% 194.496
17/12/2024 50,65 50,90 50,20 50,60 -0,49% 1,38% 262.162
16/12/2024 50,90 50,90 50,35 50,85 +0,39% 1,08% 203.699
13/12/2024 51,15 51,20 50,50 50,65 -1,07% 1,37% 248.612
12/12/2024 51,05 51,20 50,85 51,20 +0,20% 0,69% 223.569